Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan Oronsky

Showing results (111-120 of 115) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 115 results.
Translational Oncology|April 17, 2016
Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical TrialMichelle M Kim, Hemant Parmar, Yue Cao, et al.
Cancer Gene Therapy|December 25, 2023
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumorsAnthony P Conley, Christina L Roland, Alberto Bessudo, et al.
Case Reports in Oncology|May 18, 2017
RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological TumorChristina Brzezniak, Bryan Oronsky, Jane Trepel, et al.
The Lancet. Oncology|August 23, 2015
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 studyTony Reid, Bryan Oronsky, Jan Scicinski, et al.
Expert Opinion on Investigational Drugs|December 10, 2016
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trialsBryan Oronsky, Ramasamy Paulmurugan, Kira Foygel, et al.
Pageof 12

Showing results (111-120 of 115) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 115 results.
Translational Oncology|April 17, 2016
Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical TrialMichelle M Kim, Hemant Parmar, Yue Cao, et al.
Cancer Gene Therapy|December 25, 2023
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumorsAnthony P Conley, Christina L Roland, Alberto Bessudo, et al.
Case Reports in Oncology|May 18, 2017
RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological TumorChristina Brzezniak, Bryan Oronsky, Jane Trepel, et al.
The Lancet. Oncology|August 23, 2015
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 studyTony Reid, Bryan Oronsky, Jan Scicinski, et al.
Expert Opinion on Investigational Drugs|December 10, 2016
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trialsBryan Oronsky, Ramasamy Paulmurugan, Kira Foygel, et al.
Pageof 12